Can­cer as­so­ci­a­tion says na­tion­al bud­get deal threat­ens re­search fund­ing

As the US House of Rep­re­sen­ta­tives is ex­pect­ed to vote this evening on a deal that would raise the na­tion’s debt ceil­ing, some bio­phar­ma in­dus­try ad­vo­cates wor­ry about how pro­posed bud­get re­stric­tions could af­fect drug re­search.

The pro­posed bud­get deal in­cludes rel­a­tive­ly flat fund­ing for non-de­fense spend­ing over the next fis­cal year, and a 1% in­crease in fis­cal year 2025, which the As­so­ci­a­tion for Clin­i­cal On­col­o­gy said on Wednes­day would “con­sid­er­ably re­strict po­ten­tial re­sources for the Na­tion­al In­sti­tutes of Health (NIH) and Na­tion­al Can­cer In­sti­tute (NCI) at a time when sci­en­tists are on the cusp of so many promis­ing can­cer dis­cov­er­ies.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.